Is Atomera’s (ATOM) MST Progress With Gate-All-Around Tech Reframing Its Core Investment Story?

• In February 2026, Atomera Incorporated reported fourth-quarter 2025 sales of US$50,000 with a net loss of US$4.43 million, and full-year 2025 sales of US$65,000 with a net loss of US$20.17 million, alongside updated Delaware law-aligned bylaws.
• Alongside these results, Atomera highlighted progress integrating its MST technology into advanced Gate-All-Around transistor structures and GaN-on-silicon applications, supported by a new major equipment OEM partnership and collaborations with leading foundries.
• We’ll now explore how Atomera’s Gate-All-Around MST progress and new equipment OEM partnership affect the company’s existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 27 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Atomera Investment Narrative Recap

To own Atomera, you need to believe MST can move from promising lab results into broad commercial adoption across advanced nodes, despite very small current revenue and continued losses. The latest quarter reinforces that the near term catalyst is still concrete licensing or production deals, while the biggest risk remains long customer qualification cycles that prolong minimal sales and ongoing net losses; this update does not materially change that balance.

The most relevant announcement here is Atomera’s progress integrating MST into Gate All Around transistor structures, backed by a major equipment OEM partnership. This directly ties to the key catalyst: if top foundries validate MST in nanosheet GAA and related applications, it can support the case that Atomera’s technology is aligned with where cutting edge logic and AI centric semiconductors are heading, even though commercial adoption is still at an early stage.

Yet behind the technical progress, investors should also be aware that prolonged low revenue and continued equity funding could...

Read the full narrative on Atomera (it's free!)

Atomera's narrative projects $2.2 million revenue and $329.8 thousand earnings by 2028. This requires 289.5% yearly revenue growth and a $20.7 million earnings increase from -$20.4 million today.

Uncover how Atomera's forecasts yield a $5.00 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span roughly US$0.01 to US$145.54, underlining how far apart individual views can be. Against that backdrop, Atomera’s minimal 2025 revenue of US$65,000 and US$20.17 million net loss keep the question of if and when MST licenses scale at the center of its story, so you may want to compare several of these perspectives before forming your own view.

Explore 5 other fair value estimates on Atomera - why the stock might be worth less than half the current price!

Build Your Own Atomera Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Atomera research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• Our free Atomera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Atomera's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com